JP2022553865A5 - - Google Patents

Info

Publication number
JP2022553865A5
JP2022553865A5 JP2022526226A JP2022526226A JP2022553865A5 JP 2022553865 A5 JP2022553865 A5 JP 2022553865A5 JP 2022526226 A JP2022526226 A JP 2022526226A JP 2022526226 A JP2022526226 A JP 2022526226A JP 2022553865 A5 JP2022553865 A5 JP 2022553865A5
Authority
JP
Japan
Application number
JP2022526226A
Other languages
Japanese (ja)
Other versions
JP7690470B2 (ja
JP2022553865A (ja
JPWO2021092322A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059329 external-priority patent/WO2021092322A1/en
Publication of JP2022553865A publication Critical patent/JP2022553865A/ja
Publication of JPWO2021092322A5 publication Critical patent/JPWO2021092322A5/ja
Publication of JP2022553865A5 publication Critical patent/JP2022553865A5/ja
Priority to JP2025089886A priority Critical patent/JP2025143254A/ja
Application granted granted Critical
Publication of JP7690470B2 publication Critical patent/JP7690470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526226A 2019-11-06 2020-11-06 がん幹細胞を標的化するがん治療 Active JP7690470B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025089886A JP2025143254A (ja) 2019-11-06 2025-05-29 がん幹細胞を標的化するがん治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
US62/931,531 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025089886A Division JP2025143254A (ja) 2019-11-06 2025-05-29 がん幹細胞を標的化するがん治療

Publications (4)

Publication Number Publication Date
JP2022553865A JP2022553865A (ja) 2022-12-26
JPWO2021092322A5 JPWO2021092322A5 (https=) 2023-11-14
JP2022553865A5 true JP2022553865A5 (https=) 2023-11-14
JP7690470B2 JP7690470B2 (ja) 2025-06-10

Family

ID=73643356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526226A Active JP7690470B2 (ja) 2019-11-06 2020-11-06 がん幹細胞を標的化するがん治療
JP2025089886A Pending JP2025143254A (ja) 2019-11-06 2025-05-29 がん幹細胞を標的化するがん治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025089886A Pending JP2025143254A (ja) 2019-11-06 2025-05-29 がん幹細胞を標的化するがん治療

Country Status (12)

Country Link
EP (1) EP4055008A1 (https=)
JP (2) JP7690470B2 (https=)
KR (1) KR20220110744A (https=)
CN (2) CN119930509A (https=)
AU (1) AU2020378067A1 (https=)
BR (1) BR112022008753A2 (https=)
CA (1) CA3157315A1 (https=)
CO (1) CO2022007910A2 (https=)
IL (1) IL292718A (https=)
MX (1) MX2022005445A (https=)
PH (1) PH12022551081A1 (https=)
WO (1) WO2021092322A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン,インコーポレーテッド Nampt阻害剤とその使用
WO2024049225A1 (ko) 2022-09-01 2024-03-07 주식회사 엘지에너지솔루션 이차 전지 및 이를 포함하는 디바이스
CN116139141A (zh) * 2022-12-14 2023-05-23 复旦大学 Agk2促进肝癌的免疫治疗的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
HK1211832A1 (zh) 2012-05-07 2016-10-14 The General Hospital Corporation 用於癌症療法的抗高血壓藥物的新穎配方及用法
ES2774330T3 (es) 2013-04-09 2020-07-20 Massachusetts Inst Technology Polímero de suministro de fármaco y usos del mismo
TW201625641A (zh) * 2014-05-22 2016-07-16 健臻公司 Nampt抑制劑及方法
US11078195B2 (en) * 2016-03-17 2021-08-03 Checkmate Therapeutics Inc. Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
KR102831570B1 (ko) * 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료

Similar Documents

Publication Publication Date Title
JP2022553865A5 (https=)
CN306402879S (https=)
CN306051601S (https=)
CN305600387S (https=)
CN306406605S (https=)
CN305717149S (https=)
CN306403946S (https=)
CN305710627S (https=)
CN306407914S (https=)
CN305645148S (https=)
CN305707971S (https=)
CN305686712S (https=)
CN306399863S (https=)
CN305685975S (https=)
CN305684362S (https=)
CN306399244S (https=)
CN305683250S (https=)
CN305682035S (https=)
CN306397987S (https=)
CN305681940S (https=)
CN306395924S (https=)
CN306395886S (https=)
CN306372429S (https=)
CN305681768S (https=)
CN306363282S (https=)